Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

Clinical trial NCT06831812 · COMPLETED

Trial details

NCT number: NCT06831812
Sponsor: Nuravax, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Alzheimer Disease Alzheimer Disease (AD)Alzheimers Disease Prevention

Start date: 2024-06-12
Primary completion: 2025-12-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.